Another US approval delay for Takeda
This article was originally published in Scrip
Takedahas suffered a US approval delay for another of its products, this time the proton pump inhibitor dexlansoprazole (TAK-390MR). The US FDAwould not be able to complete its review by the original Prescription Drug User Fee Act date in October, and this was now expected to take a further three months, the Japanese firm said. Its DPP-4 inhibitor alogliptin recently suffered a similar delay and now looks unlikely to be approved before the end of the year (Scrip Online, October 10th, 2008). Dexlansoprazole, a modified once-daily form of lansoprazole, was filed in December 2007 for treating the symptoms of gastro-oesophageal reflux disease and healing/maintenance use in erosive oesophagitis.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.